Antipsychotic Extrapyramidal Side Effects: GPAT Study Notes

Introduction to Antipsychotics and Extrapyramidal Symptoms

Antipsychotic medications, also known as neuroleptics, represent the cornerstone of therapy for schizophrenia, bipolar disorder, and acute psychosis. While their efficacy in curbing positive psychotic symptoms is undisputed, their adverse effect profile remains a major clinical challenge and a top tier subject in pharmacology exams.

Among these toxicities, extrapyramidal symptoms or EPS are the most heavily evaluated in GPAT preparation and NIPER screenings. Understanding the precise molecular mechanisms, timelines of clinical onset, and rescue medications is vital for students compiling dependable Pharmacy study notes for their upcoming B.Pharm exams.

The Dopaminergic Pathways and EPS Pathophysiology

To master this Pharmacology cheat sheet topic, one must visualize the four core dopaminergic pathways in the human brain:

• Mesolimbic Pathway: Hyperactivity here drives positive symptoms such as hallucinations and delusions. Therapeutic D2 receptor blockade here reduces psychosis.
• Mesocortical Pathway: Hypoactivity here is associated with negative symptoms like avolition and flat affect.
• Tuberoinfundibular Pathway: Dopamine inhibits prolactin release. D2 blockade causes hyperprolactinemia, leading to galactorrhea, gynecomastia, and amenorrhea.
• Nigrostriatal Pathway: Dopamine modulates the basal ganglia to control motor movement and smooth motor initiation. It maintains an intricate reciprocal balance with acetylcholine.

Typical first generation antipsychotics like haloperidol, fluphenazine, and chlorpromazine block D2 receptors nonselectively. When dopamine receptor occupancy in the dorsal striatum crosses roughly 75 to 80 percent, the normal dopaminergic inhibition of cholinergic interneurons is lost. Acetylcholine levels surge unchecked, triggering the classical motor manifestations known collectively as extrapyramidal symptoms.

Classification of Extrapyramidal Side Effects

Clinical presentation of EPS follows a characteristic timeline. Pharmacy students should memorize this sequence from earliest onset to late onset complications.

1. Acute Dystonia

• Onset: Minutes to hours or within the first 24 to 96 hours of starting high potency typical neuroleptics like haloperidol.
• Clinical Features: Sustained, agonizing, involuntary muscle contractions. Common presentations include torticollis (spasmodic neck twisting), retrocollis, trismus (jaw clenching), facial grimacing, tongue protrusion, and oculogyric crisis (upward deviation of the eyes). In severe cases, laryngeal spasm can threaten the airway.
• Underlying Cause: Acute hyperdopaminergic to hypercholinergic imbalance in the striatum.
• Drug of Choice: Centrally acting anticholinergics such as intramuscular or intravenous promethazine, benztropine (1 to 2 mg), or diphenhydramine (25 to 50 mg). Oral trihexyphenidyl is maintained thereafter for prevention.

2. Akathisia

• Onset: Days to weeks following therapy initiation or dosage escalation.
• Clinical Features: An intense, subjective sensation of inner restlessness accompanied by an irresistible urge to move. Patients pace incessantly, cross and uncross their legs, tap their feet, or shift weight while standing. Akathisia is frequently misdiagnosed as worsening psychotic agitation, which leads to the dangerous error of raising the neuroleptic dose.
• Drug of Choice: Lipophilic beta blockers like propranolol (20 to 80 mg daily) are the standard first line treatment. Centrally acting anticholinergics have limited efficacy here. Low dose benzodiazepines like lorazepam or clonazepam are valid alternatives.

3. Pseudoparkinsonism

• Onset: Weeks to months after drug exposure.
• Clinical Features: The clinical triad mimics idiopathic Parkinson disease: generalized bradykinesia, lead pipe or cogwheel muscular rigidity, resting pill rolling tremors, mask like facies, stooped posture, and a festinating gait.
• Drug of Choice: Centrally acting anticholinergic agents like trihexyphenidyl (2 to 5 mg daily) or procyclidine. Amantadine, which promotes dopamine release, is also effective.
• Critical Exam Rule: Never administer levodopa to treat drug induced parkinsonism, because levodopa stimulates the mesolimbic pathway and precipitates acute psychosis.

4. Tardive Dyskinesia

• Onset: Months to years of chronic antipsychotic treatment. It is a late onset and potentially irreversible disorder.
• Clinical Features: Involuntary, repetitive, choreoathetoid movements affecting the orofacial musculature, known as the bucco linguo masticatory syndrome. Manifestations include tongue thrusting (fly catcher tongue), lip smacking, puckering, grimacing, and choreiform movements of fingers and toes.
• Underlying Cause: Chronic D2 blockade produces compensatory upregulation and dopamine receptor supersensitivity in the striatum.
• Crucial Exam Pearl: Anticholinergic drugs dramatically worsen tardive dyskinesia!
• Management: Gradually withdraw the offending typical agent. Switch the patient to an atypical antipsychotic with low EPS potential like clozapine or quetiapine. Vesicular monoamine transporter 2 (VMAT2) inhibitors such as valbenazine or deutetrabenazine are approved as targeted therapies.

5. Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is an idiosyncratic, life threatening medical emergency caused by profound central dopamine depletion.

• Clinical Tetrad: Hyperpyrexia (temperatures often exceeding 40 degrees Celsius), extreme generalized lead pipe rigidity, autonomic instability (fluctuating blood pressure, tachycardia, diaphoresis), and altered mental status ranging from confusion to coma.
• Laboratory Findings: Massive elevation in serum creatine kinase due to severe rhabdomyolysis, leukocytosis, and elevated transaminases. Acute renal failure can develop from myoglobinuria.
• Emergency Management:
  1. Immediately discontinue the neuroleptic agent.
  2. Initiate aggressive physical cooling and intravenous hydration.
  3. Administer dantrolene sodium (1 to 2.5 mg per kg intravenously), a direct acting skeletal muscle relaxant that blocks ryanodine receptors on the sarcoplasmic reticulum to curb malignant hyperthermia.
  4. Administer dopamine agonists like bromocriptine or amantadine to restore dopaminergic tone.

High Yield Antipsychotic Potency Comparison

• Haloperidol and Fluphenazine: Very high D2 receptor affinity. High incidence of acute dystonia, akathisia, and pseudoparkinsonism, but negligible anticholinergic, sedative, or hypotensive side effects.
• Chlorpromazine and Thioridazine: Low D2 receptor affinity with high anticholinergic, antihistaminic, and alpha adrenergic blocking actions. Lower incidence of EPS, but pronounced sedation, postural hypotension, and weight gain.
• Atypical Antipsychotics (Clozapine, Olanzapine, Quetiapine): Possess combined 5 HT2A and D2 antagonism. Rapid dissociation from D2 receptors results in minimal EPS risk. Clozapine displays virtually zero extrapyramidal liability, though it carries risks of agranulocytosis and seizures.
• Aripiprazole: Acts as a partial D2 agonist. It carries a low risk of dystonia and parkinsonism, but causes noticeable akathisia in sensitive individuals.

High Yield Tips for Pharmacy Examinations

1. Diphenhydramine works in acute dystonia due to its potent central anticholinergic properties, not its H1 blocking action.
2. Propranolol crosses the blood brain barrier effortlessly and is the most effective pharmacotherapy for akathisia.
3. Anticholinergic withdrawal can unmask or exacerbate tardive dyskinesia.
4. Dantrolene acts peripherally on muscle cells, whereas bromocriptine acts centrally on dopamine receptors during neuroleptic malignant syndrome treatment.

Summary

Extrapyramidal side effects represent a major clinical hurdle caused by antipsychotic D2 receptor blockade within the nigrostriatal pathway. The conditions appear across a predictable timeline, beginning with acute dystonia (treated with anticholinergics), moving through akathisia (treated with propranolol) and pseudoparkinsonism, to tardive dyskinesia and neuroleptic malignant syndrome. Memorizing these timeframes, causative receptor dynamics, and specific antidotes ensures complete preparation for pharmacology exam questions.